Prognostic Factors and Nomogram Construction for First Local Recurrent Retroperitoneal Sarcoma Following Surgical Resection: A Single Asian Cohort of 169 Cases

Aobo Zhuang¹, Weiqi Lu¹,², Yuan Fang¹, Lijie Ma¹, Jing Xu¹,², Jiongyuan Wang¹,², Hanxing Tong¹,²* and Yong Zhang¹,²*

¹ Department of General Surgery, South Hospital of the Zhongshan Hospital/Shanghai Public Health Clinical Center, Fudan University, Shanghai, China, ² Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Objective: This study aimed to explore the prognostic factors for first local recurrent retroperitoneal soft tissue sarcoma (FLR-RPS) and construct predictive nomograms in the Asian population.

Methods: In a single Asian sarcoma center, data of patients with FLR-RPS were retrospectively analyzed from January 2011 to September 2020. We developed and internally validated prognostic factors determined by the Cox regression model, as well as nomograms for predicting recurrence-free survival (RFS) and overall survival (OS). The concordance index and calibration curve were used to determine the nomogram’s discriminative and predictive ability.

Results: With 169 patients, the median follow-up duration was 48 months and the 5-year OS rate was 60.9% (95% confidence interval (CI), 51.9%–69.9%). OS was correlated with chemotherapy at the time of initial surgery and tumor grading. The 5-year cumulative local recurrence rate and distant metastasis rate were 75.9% (95% CI, 67.5%–84.3%) and 10.1% (95% CI, 4.2%–16.0%), respectively, and the length of the disease-free interval following the primary operation was associated with disease recurrence. The 6-year OS and cumulative recurrence rate after surgery in our cohort were comparable with those in the TARPSWG cohort, but the proportion of local recurrence was higher (80.4% vs. 59.0%), and distant metastasis was less common (10.1% vs. 14.6%). In this study, two nomogram prediction models were established, which could predict the 1-, 2-, and 5-year OS and RFS, and the concordance indices were 0.74 and 0.70, respectively. The calibration plots were excellent.

Conclusions: For the FLR-RPS patients, some can still achieve an ideal prognosis. The treatment of FLR-RPS in Asian populations can be aided by the predictive model established in this study.

Keywords: asian, retroperitoneal sarcoma, local recurrent, prognosis, nomogram, recurrence-free survival (RFS), overall survival (OS)
INTRODUCTION

Soft tissue sarcoma is a rare malignant tumor, which accounts for less than 1% of all neoplasm (1). Soft tissue sarcoma that originates in the retroperitoneal space accounts for approximately 15% (2). Even with complete resection, more than half of retroperitoneal sarcoma (RPS) still suffer from local recurrence (LR) within 5 years (3). With prolonged follow-up, the LR rate can reach as high as ~90% at 10 years (4) and is the primary cause of mortality (5). Most patients with LR die from small bowel obstruction or cachexia (6, 7). The resectability of recurrent disease is the most important prognostic factor. Specifically, the median survival time for patients with resection of the lesion is 60 months, whereas that with the unresectable disease is only 20 months (8). LR retroperitoneal liposarcoma patients who had monthly growth rates of less than 9 mm and underwent surgical resection had a considerably better prognosis than patients who had monthly growth rates larger than 9 mm, according to Park et al., who focused on first local recurrent RPS (FLR-RPS) (9). Yang et al. reported that the interval between high-grade tumors and disease-free interval (DFI) less than 1 year was a poor prognostic factor for patients with FLR-RPS (10). Similarly, Gronchi and colleagues previously showed that well-differentiated liposarcoma histology subtype and DFI were independent predictors for LR (11). Recently, an Asian sarcoma center published a cohort of 53 patients and discovered that Asian patients with FLR-RPS were younger, had longer DFI, and had a higher tumor burden compared with Western populations. However, due to the limited sample size, it was unable to explore relevant prognostic variables in the Asian population (12).

The nomogram, a predictive tool that incorporates a variety of clinicopathological variables, can effectively be used for individualized treatments. In 2019, Raut et al. reported the outcomes of the largest FLR-RPS set derived from the data of 602 patients with first-time LR of RPS in 22 centers and proposed a new prognostic nomogram (TARPSWG nomogram) using factors including age at second surgery, multifocality, grade, completeness of second surgery, histology, chemotherapy/radiotherapy at first surgery, and the number of organs resected at first surgery (13). To reliably predict the 6-year disease-free survival (DFS) and overall survival (OS) of patients who underwent resection for locally recurrent retroperitoneal sarcoma, the TARPSWG nomogram can be used; however, its research is based on a cohort of European and American populations and without external verification, and it only predicts the patient’s condition at the sixth year after surgery; therefore, its practicality is limited. Moreover, Hui et al. conducted an external validation study on the TARPSWG nomogram using a 53-person Asian cohort. Given the disparities between the Asian cohort and the Western cohort, the concordance indices for 6-year DFS were only 0.65 (12). Therefore, its ability to accurately forecast outcomes in the Asian population needs improvement.

Hence, the purpose of this study is to use the large-sample cohort of a high-flow sarcoma center to explore the prognostic factors of FLR-RPS in the Asian population, as well as to establish prognostic nomograms.

METHODS

Patient Cohort

Between January 2011 to September 2020 at the South Hospital of the Zhongshan Hospital/Shanghai Public Health Clinical Center, Fudan University, Shanghai, China, 169 patients with curative intent were included. Inclusion criteria were as follows: (1) retroperitoneally located primary tumor, (2) well-differentiated liposarcoma (WDLPS), dedifferentiated liposarcoma (DDLPS), leiomyosarcoma (LMS), malignant peripheral nervesheath tumor (MPNST), solitary fibrous tumor (SFT), and others (including unclassified/undifferentiated pleomorphic sarcoma, myxoliposarcoma, and pleomorphic liposarcoma) confirmed by pathology (13), (3) no distant metastasis, (4) first relapse, and (5) complete follow-up data. The ethics committee of the South Hospital of Zhongshan Hospital/Shanghai Public Health Clinical Center accepted this study and conducted it in compliance with the Declaration of Helsinki.

The first radical surgical resection of primary RPS was defined as “primary surgery”. “Second surgery” was defined as curative-intent surgery for the first LR. The sum of the diameter of all tumors documented in the surgical record was used to calculate the tumor burden. Complete resection was defined as negative margins (R0) or positive micromargins (R1) but without positive gross margin resection (R2). In accordance with the National Federation of Centers for the Fight Against Cancer (FNCLCC) classification system, all RPS were assigned to one of three grades: grade 1, 2, or 3 (14). DFI was defined as the time from previous operation to the diagnosis of recurrence and was considered a continuous variable.

Postoperative Follow-Up

Follow-up data, including clinical and imaging examination results, disease progression, and death were collected (CT or MRI from chest to pelvis). Follow-up examinations were performed every 3 months for 2 years, then every 6 months for 3 years, and once a year after 5 years. The radiographic emergence of a new lesion or considerable expansion of the original lesion was used to indicate disease recurrence.

Statistical Analysis

Recurrences inside the ipsilateral retroperitoneum, peritoneal cavity, or pelvis were categorized as LR. The second postoperative LR, distant metastasis (DM), or death without recurrence were all defined as the end-point event of DFS, whereas the time between the second surgery to the second recurrence of the disease is classified as recurrence-free survival (RFS). LR combined with DM was recorded as a DM event. Disease recurrence included LR and DM. The survival curve was estimated using the Kaplan–Meier method, and the log-rank test was performed to determine the statistical significance between groups. The crude cumulative incidence curves for LR and DM were calculated in the competitive risk framework. In the analysis of LR (DM), deaths without evidence of disease were considered
to be concurrent occurrences with DM (LR). The advancement of the residual tumor following surgery was classified as a LR in the subgroup of patients who underwent $R^2$ resection.

Univariate Cox proportional hazards analysis was used to examine the impact of various clinicopathological parameters on survival and recurrence, and variables ($p < 0.05$) were further incorporated into the multivariate Cox model. As for variable selection, all clinicopathological variables were included, and a backward procedure based on the Akaike Information Criterion was applied. It was developed using a multivariate Cox model that included the chosen variable. Discrimination was measured using Harrell C’s consistency index ($15$). An estimated survival probability was used to split the patients into four groups for calibration. This graph was created by calculating a mean and 95% confidence interval for the survival probability of each subgroup before creating it.

All tests were two-tailed, and a $p < 0.05$ was considered statistically significant. All data were analyzed using the SPSS 22.0 (SPSS Inc., Chicago, IL, USA) and R 4.0.4 (R Foundation for Statistical Computing, Vienna, Austria; http://www.r-project.org/).

RESULTS

Patient and Tumor Characteristics
The median follow-up time was 48 (range, 0.3–120) months. Patient characteristics are listed in Tables 1 and 2. Sixty-three (37.3%), 50 (29.6%), 29 (17.2%), 6 (3.6%), 4 (2.4%), and 17 (10.1%) cases were diagnosed with WDLPS, DDLPS, LMS, MPNST, SFT, and others, respectively. According to the FNCLCC classification, 60 (35.5%) cases were defined as grade 1, 59 (34.9%) as grade 2, and 50 (29.6%) as grade 3 tumors (Table 2). For primary surgery, the median age was 51 (range, 24–82) years, 7 (4.1%) received laparoscopic surgery, and most patients had complete resection (95.9%). The median number of combined resections was 0 (range, 0–5). The median DFI after primary surgery was 14 (range, 0.5–341.9) months (Table 1). For second surgery, the median age was 54 (range, 26–84) years. Most patients (94.7%) with complete resection had a median number of combined resections of 2 (range, 0–6). The median tumor burden was 15 (range, 2–55) cm and 44 (26.0%) had multifocal diseases. Twenty-one (12.4%) patients received external beam radiation therapy, and 36 (21.3%) received chemotherapy. The median estimated blood loss was 500 (range, 10–4,500) ml. Intraoperatively packed RBC transfusion was administered in 63 (37.3%) patients, with a median transfusion of 4 (range, 2–14) units. Major postoperative complications occurred in 21 (12.4%) patients, and 5 (2.9%) patients died within 90 days after surgery. The median postoperative hospital stay of all patients was 16 (range, 7–208) days (Table 2).

Disease Recurrence Analysis
The median DFI after second surgery was 19 months (range, 8–57), and the 1-, 2-, and 5-year RFS rate were 62.9% (95% CI, 55.5%–70.3%), 44.8% (95% CI, 36.8%–52.8%), and 23.5% (95% CI, 15.8%–31.7%), respectively. The 1-, 2-, and 5-year crude cumulative incidence for second LR and DM were 34.9% (95% CI, 27.5%–42.43%) and 4.3% (95% CI, 1.0%–7.6%), 51.8% (95% CI, 43.6%–60.0%) and 10.1% (95% CI, 4.2%–16.0%), and 75.9% (95% CI, 67.5%–84.3%) and 10.1% (95% CI, 4.2%–16.0%), respectively (Figure 1A).

The univariate analysis for prognostic factors of disease recurrence in patients undergoing resection for first LR is shown in Table 3. Disease recurrence was strongly correlated with histologic subtype ($p = 0.002$). The crude cumulative incidence for LR and DM at 5-year for WDLPS, DDLPS, LMS, MPNST, SFT, and others were 72.7% (95% CI, 59.1%–84.3%) and 0% (95% CI, 0%–0%), 88.8% (95% CI, 81.0%–99.6%) and 4.4% (95% CI, 0%–10.5%), 47.7% (95% CI, 24.9%–70.4%) and 38.1% (95% CI, 18.1%–58.1%), NA and NA, 23.3% (95% CI, 0%–76.7%) and NA, and 80.6% (95% CI, 57.1%–100.0%) and 0% (95% CI, 0%–0%), respectively (Figures 1B, C). Grade 3 tumors exhibited a greater postoperative recurrence risk ($p = 0.001$) than grades 1–2 tumors. Shorter DFI was also a risk factor for postoperative recurrence.

| TABLE 1 | Patient and tumor characteristics in 169 patients with primary surgery. |
|--------------------------|--------------------------|--------------------------|
| Characteristics              | $N = 169$            | % of total |
| Age [years, median (range)] | 51                         | 24–82       |
| Operation                  |                           |             |
| Laparoscopic surgery        | 7                          | 4.1         |
| Open surgery                | 162                        | 95.9        |
| Complete resection          |                           |             |
| Yes                        | 159                       | 94.1        |
| No                         | 10                        | 5.9         |
| Number of combined resections [median (range)] | 0                       | 0–5         |
| Radiation                  |                           |             |
| Yes                        | 5                          | 3.0         |
| No                         | 164                       | 97.0        |
| Chemotherapy                |                           |             |
| Yes                        | 17                         | 10.1        |
| No                         | 152                       | 89.9        |
| DFI after first surgery [median (range)] | 14                      | 0.5–341.9   |

DFI, disease-free interval.
Multifocality, radiation, chemotherapy, high predicted blood loss, longer operative time, and occurrence of postoperative complications were also related to disease recurrence in univariate analysis.

In multivariate analysis, only DFI was an independent risk factor (HR 0.989, p = 0.004) for postoperative disease recurrence (Table 3). Additionally, decided by the “x-tile” program, we split DFI into long-DFI and short-DFI groups (with a cutoff month of 50) (16). The 5-year cumulative recurrence rate of the long-DFI and short-DFI groups were 47.7% (95% CI, 22.6%–69.8%) and 85.3% (95% CI, 81.5%–93.1%), respectively (Figure 1D), with a significant difference between the subgroups (p < 0.001).

Overall Survival Analysis
At the most recent checkup, 62 (36.7%) patients were dead throughout the whole group. After removing 5 cases of postoperative deaths, the OS rate at 1, 2, and 5 years was 90.7% (95% CI, 86.2%–95.2.0%), 77.4% (95% CI, 70.7%–84.1%), and 60.9% (95% CI, 51.9%–69.9%), respectively (Figure 2A). The 1-, 2-, and 5-year DFS rate were 58.2% (95% CI, 50.8%–65.6%), 40.2% (95% CI, 32.8%–47.6%), and 20.4% (95% CI, 27.8%–13.0%), respectively (Figure 2B). The median time from surgery to death was 21.1 (range, 0.8–85.1) months. The 5-year OS for WDLPS, DDLPS, LMS, MPNST, SFT, and others were 71.7% (95% CI, 57.2%–86.2%), 50.9% (95% CI, 33.8%–68.0%), 63.5% (95% CI, 42.2%–84.8%), NA, 50% (95% CI, 37.3%–67.3%), respectively.

### Table 2: Patient and tumor characteristics in 169 patients with second surgery.

| Characteristics                        | N = 169 | % of total |
|----------------------------------------|---------|------------|
| Gender                                 |         |            |
| Men                                    | 65      | 38.5       |
| Women                                  | 104     | 61.5       |
| Age [years, median (range)]            | 54      | 26–54      |
| ASA score                              |         |            |
| 1                                      | 130     | 76.9       |
| >1                                     | 39      | 23.1       |
| Operation                              |         |            |
| Laparoscopic surgery                   | 0       | 0          |
| Open surgery                           | 169     | 100        |
| Complete resection                     |         |            |
| Yes                                    | 160     | 94.7       |
| No                                     | 9       | 5.3        |
| Number of combined resections [median (range)] | 2      | 0–6        |
| Tumor burden [cm, median (range)]      | 15      | 2–56       |
| Histologic subtypes                    |         |            |
| WDLPS                                  | 63      | 37.3       |
| DDLPS                                  | 50      | 29.6       |
| LMS                                    | 29      | 17.2       |
| SFT                                    | 4       | 2.4        |
| MPNST                                  | 6       | 3.6        |
| Other                                  | 17      | 10.1       |
| Multifocality                          |         |            |
| No                                     | 125     | 74.0       |
| Yes                                    | 44      | 26.0       |
| FNCLCC                                  |         |            |
| Grade 1                                | 60      | 35.5       |
| Grade 2                                | 59      | 34.9       |
| Grade 3                                | 50      | 29.6       |
| Radiation                              |         |            |
| Yes                                    | 21      | 12.4       |
| No                                     | 148     | 87.6       |
| Chemotherapy                           |         |            |
| Yes                                    | 36      | 21.3       |
| No                                     | 133     | 78.7       |
| Operative time [h, median (range)]     | 4       | 1–12       |
| Estimated blood loss [ml, median (range)] | 500   | 10–4,500   |
| Packed RBC transfusion                 |         |            |
| Yes                                    | 63      | 37.3       |
| No                                     | 106     | 62.7       |
| Clavien–Dindo classification           |         |            |
| NA                                     | 108     | 63.9       |
| 1–2                                    | 40      | 23.7       |
| 3–5                                    | 21      | 12.4       |
| Postoperative hospital stay [days, median (range)] | 16     | 7–208      |

WDLPS, well-differentiated liposarcoma; DDLPS, dedifferentiated liposarcoma; LMS, leiomyosarcoma; SFT, solitary fibrous tumor; MPNST, malignant peripheral nerve sheath tumor; FNCLCC, The National Federation of Centres for the Fight Against Cancer.

Zhuang et al. First Local Recurrent Retroperitoneal Sarcoma

Frontiers in Oncology | www.frontiersin.org
April 2022 | Volume 12 | Article 856754
FIGURE 1 | Cumulative incidence in patients after a second surgery for all patients: (A) all, (B) local recurrence, (C) distant metastasis, and (D) long disease-free interval group and short disease-free interval group.

TABLE 3 | Univariable and multivariable analyses to determine the independent predictors of disease recurrence.

| Variables at second surgery | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|----------------------|
| Gender men vs. women       | 0.857 (0.578–1.272) | 0.444                |
| Histologic subtypes         | 0.002               |                      |
| DDLPS vs. WDLPS             | 2.242 (1.530–3.841) | 1.846 (1.063–3.212) |
| LMS vs. WDLPS               | 1.243 (0.703–2.197) | 1.296 (0.674–2.493) |
| MPNST vs. WDLPS             | 3.020 (1.063–8.582) | 1.684 (0.538–5.267) |
| SFT vs. WDLPS               | 0.422 (0.058–3.089) | 0.447 (0.080–3.318) |
| Other vs. WDLPS             | 2.044 (1.058–3.992) | 1.405 (0.678–2.671) |
| FNCLCC grade (3 vs. 1–2)    | 1.953 (0.306–2.921) | 0.001 1.122 (0.674–1.807) 0.527 |
| DFI after first surgery (continuous) | 0.988 (0.981–0.995) | 0.001 0.989 (0.982–0.997) 0.004 |

| Variables at first surgery  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|----------------------|
| Complete resection (yes vs. no) | 0.996 (0.980–1.012) | 0.585                |
| Number of combined resections (continuous) | 0.895 (0.364–2.202) | 0.810 1.025 (0.998–1.052) 0.075 |
| Multifocality (yes vs. no)  | 1.102 (0.964–1.260) | 0.154                |
| Radiation (yes vs. no)      | 0.912 (0.520–1.602) | 0.749                |
| Chemotherapy (yes vs. no)   | 1.757 (1.126–2.741) | 0.013 1.307 (0.787–2.170) 0.301 |
| Operative time (continuous) | 1.181 (1.057–1.319) | 0.003 1.086 (0.942–1.252) 0.255 |
| Estimated blood loss (continuous) | 1.000 (1.000–1.001) | 0.008 1.000 (1.000–1.001) 0.621 |
| Packed RBC transfusion (yes vs. no) | 1.444 (0.980–2.128) | 0.065 1.403 (0.918–2.144) 0.118 |
| Clavien–Dindo classification (1–5 vs. NA) | 1.916 (1.302–2.820) | 0.001 1.005 (0.999–1.010) 0.097 |
| Postoperative hospital stay (continuous) | 1.005 (0.999–1.010) | 0.097 0.934 (0.636–1.371) 0.728 |

WDLPS, well-differentiated liposarcoma; DDLPS, dedifferentiated liposarcoma; LMS, leiomyosarcoma; SFT, solitary fibrous tumor; MPNST, malignant peripheral nerve sheath tumor; FNCLCC, The National Federation of Centres for the Fight Against Cancer; DFI, disease-free interval.
CI, 4.9%–95.1%), and 47.7% (95% CI, 20.5%–74.9%), respectively (Figure 2C).

The univariate analysis results of risk factors for OS are shown in Table 4. FNCLCC grade ($p = 0.008$), number of combined resections ($p < 0.001$), operative time ($p < 0.001$), estimated blood loss ($p < 0.001$), packed RBC transfusion ($p < 0.001$), postoperative complication ($p = 0.003$), and chemotherapy at primary surgery ($p = 0.005$) were related to OS in univariate analysis.

FNCLCC grade, grade 3 vs. grades 1–2 (HR 2.014, $p = 0.015$), and chemotherapy at primary surgery (HR 1.040, $p = 0.020$) were shown to be substantially linked with OS in multivariate Cox analysis.

**Construction and Validation of Nomograms**

All clinical variables mentioned above were included in the Cox regression analysis, and backward stepwise selection was performed using a likelihood ratio test with Akaike Information Criterion as the stopping criteria. FNCLCC grade, age, number of combined resections, packed RBC transfusion, Clavien–Dindo classification, postoperative hospital stay, complete resection at primary surgery, and chemotherapy/radiotherapy at primary surgery were selected to build the OS nomogram (Figure 3), and FNCLCC grade, DFI, multifocality, estimated blood loss, Clavien–Dindo classification, and number of combined resections at primary surgery were chosen to construct the RFS nomogram (Figure 4). The calibration plots (Figures 3, 4) demonstrated a high degree of agreement between the nomogram predictions and observed results. The concordance indices were 0.74 (95% CI, 6.1–8.6) for the OS nomogram and 0.70 (95% CI, 0.60–0.79) for the RFS nomogram.

The TARPSWG nomogram was then externally validated using our cohort, and the DFS and OS nomograms had concordance indices of 0.67 and 0.65, respectively.

**DISCUSSION**

Soft tissue sarcoma is a rare malignant tumor that accounts for less than 1% of all neoplasm, with around 15% of cases occurring in the retroperitoneal space (17). Surgery is the primary means of curative treatment; however, a large proportion of patients still experience disease recurrence. The mortality rate of RPS is mainly due to LR, and up to 70% of deaths, even when there is no indication of DM (6, 7, 9). Meanwhile, there has been a growth in nomograms being used to predict the prognosis of RPS patients, and several nomograms have been developed to optimize the predictive performance of the disease recurrence and OS of RPS (13, 18, 19). Among them, TARPSWG used multicenter data of European and American populations in 2019 to establish nomogram prediction models for the prognosis of the first relapse of local recurrent retroperitoneal sarcoma. They demonstrated high calibration and the discriminative ability for OS and DFS (C index of 0.70 and 0.67, respectively) (13). In November 2021, Hui et al. performed an external validation of the above nomogram using an Asian cohort of 53 patients; the concordance indices for the 6-year OS was 0.7, but only 0.65 for the 6-year DFS (12), which is consistent with the external validation results in our study (the concordance indices for the
TABLE 4 | Univariable and multivariable analyses to determine the independent predictors of overall survival.

| Variables | Univariate analysis | Multivariate analysis |
|-----------|---------------------|----------------------|
|           | Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value |
| Gender | 1.060 (0.813–1.381) | 0.668 | | |
| Histologic subtypes | 2.148 (1.111–4.151) | 0.067 | | |
| DDLPS vs. WDLPS | 1.235 (0.528–2.887) | 0.326 | | |
| MFS vs. WDLPS | 4.910 (1.404–17.178) | 0.130 | | |
| SFT vs. WDLPS | 2.205 (0.507–9.598) | 0.369 | | |
| Other vs. WDLPS | 2.212 (0.943–5.191) | 0.078 | | |
| FNCLCC grade (3 vs. 1–2) | 2.043 (1.201–3.476) | 0.008 | 2.014 (1.146–3.541) | 0.015 |
| DFI after first surgery (continuous) | 0.996 (0.988–1.004) | 0.376 | | |

Variables at second surgery

| Age (continuous) | 1.022 (0.998–1.046) | 0.068 |
| Complete resection (yes vs. no) | 1.072 (0.599–1.917) | 0.815 |
| Number of combined resections (continuous) | 1.375 (1.151–1.642) | <0.001 |
| Multifocality (yes vs. no) | 1.428 (0.808–2.523) | 0.220 |
| Radiation (yes vs. no) | 0.950 (0.429–2.104) | 0.900 |
| Chemotherapy (yes vs. no) | 1.310 (0.701–2.446) | 0.397 |
| Operative time (continuous) | 1.381 (1.191–1.601) | <0.001 |
| Estimated blood loss (continuous) | 1.001 (1.000–1.001) | 0.003 |
| Packed RBC transfusion (yes vs. no) | 2.725 (1.616–4.594) | <0.001 |
| Clavien-Dindo classification (1–5 vs. NA) | 2.203 (1.308–3.711) | 0.003 |
| Postoperative hospital stay (continuous) | 0.998 (0.988–1.007) | 0.639 |

Variables at first surgery

| Complete resection (yes vs. no) | 0.851 (0.476–1.524) | 0.588 |
| Number of combined resections (continuous) | 1.069 (0.789–1.447) | 0.669 |
| Radiation (yes vs. no) | 0.962 (0.725–1.277) | 0.791 |
| Chemotherapy (yes vs. no) | 1.047 (1.014–1.081) | 0.005 |

Hazard ratio (95% CI) $p$-value

WDLPS, well-differentiated liposarcoma; DDLPS, dedifferentiated liposarcoma; LMS, leiomyosarcoma; SFT, solitary fibrous tumor; MPNST, malignant peripheral nerve sheath tumor; FNCLCC, The National Federation of Centres for the Fight Against Cancer; DFI, disease-free interval.

6-year OS and DFS were 0.67 and 0.65, respectively. However, the study of Hui et al. did not investigate the prognostic variables of the Asian population due to the limited sample size. Prognostic factors of FLR-RPS in the Asian population were studied for the first time in this study and found that FNCLCC classification and chemotherapy during the initial surgery were independent prognostic factors of OS and a shorter DFI was linked to postoperative disease recurrence. We established two nomogram prediction models that could successfully predict 1-, 2-, and 5-year OS rate and RFS rate in patients with LR-RPS throughout the same time period.

Both the TARPSWG and our cohorts had comparable and dissimilar prognoses, as seen below. Firstly, the 6-year OS of the TARPSWG set and ours is consistent (54.1% vs. 57.4%), which is significantly higher than the nonsurgical cohort linked to recurrence described in the prior literature (20–22); secondly, the median DFI after the second surgery in the two groups were the same (both 19 months) but is significantly shorter than that of the primary operation [TARPSWG in 2016 reported a median time to LR of primary retroperitoneal tumors after surgery of 39 months (23)]. There are some differences between Asian and Western patients with LR-RPS as well. [1] The 6-year cumulative recurrence rate is higher in our cohort (76.4% vs. 82.4%), and the 6-year cumulative LR is also higher (80.4% vs. 59.0%), but distant metastasis is lower (10.1% vs. 14.6%). First, our cohort had a greater percentage of WDLPS (37.3% vs. 28.1%), and second, the recurrence of WDLPS was frequently local and did not include distant metastasis, both of which are likely contributors to the aforementioned discrepancies (24). Secondly, the proportion of grade 3 in the TARPSWG set was higher (39.4% vs. 29.6%), the risk of distant metastasis of high-grade sarcoma was higher, and the risk of LR was relatively low (23). [2] The Asian cohort (ours and Hu’s) were younger and had a higher tumor burden than the European and American cohorts (TARPSWG cohort).

Our study indicated that DFI was the sole independent prognostic factor for disease recurrence in the examination of risk variables. Specifically, a shorter DFI after primary surgery was associated with a higher risk of recurrence. In FLR-RPS patients undergoing surgery, Yang and colleagues have reported that DFI of less than 1 year was a poor prognostic factor (10). Time to recurrence also exerts significant influence over complete resection rates for recurrent disease (25). DFI’s optimal cutoff value was determined by further using the x-tile software to guide clinical practice. Within 5 years, 85.3% of patients in the short-DFI group experienced disease recurrence, compared with just 47.7% of patients in the long-DFI group when the cutoff value was 50 months. Therefore, the interval between follow-up following second surgery should be decreased if the duration from initial resection to disease recurrence is shorter than 4 years.

In the multivariate analysis of OS-related factors, FNCLCC grade was revealed as an independent prognostic parameter. The degree of tumor differentiation, rate of mitosis, and degree of necrosis are the three primary variables for the globally accepted
FIGURE 3 | (A) Nomogram for 1-, 2-, and 5-year overall survival in patients with first local recurrent retroperitoneal sarcoma and calibration plots for internal validation of (B) 1-, (C) 2-, and (D) 5-year overall survival nomogram.

FIGURE 4 | (A) Nomogram for 1-, 2-, and 5-year recurrence-free survival in patients with first local recurrent retroperitoneal sarcoma and calibration plots for internal validation of (B) 1-, (C) 2-, and (D) 5-year recurrence-free survival nomogram.
FNCLCC classification. Various factors, such as mitosis rate, degree of necrosis, and degree of tumor differentiation, are considered by clinicians when determining the grade based on the sum of the scores. Twofold ($p = 0.015$) greater risk of mortality was seen for high-grade sarcoma compared with low-grade FNCLCC in this analysis, which is consistent with the conclusions from prior studies reporting on primary or recurrent RPS (13, 22). A worse survival following second surgery for LR was also connected with initial surgical chemotherapy, as we discovered. This should not be interpreted as chemotherapy influencing the long-term survival of patients. Rather, it is more probable that patients who undergo chemotherapy have aggressive tumor biology. Patients with “high-risk” tumors are more likely to be given chemotherapy, according to a recent trend. Chemotherapy’s effect on RPS has yet to be determined. There is no conclusive evidence that preventive systemic therapy has an impact following full resection of recurrent RPS (26–28).

There are several limitations to this study. First, due to its retrospective nature, it is susceptible to subject selection bias. A second issue is that we were unable to confirm uncommon histological subtypes, such as MPNST ($n = 6$), due to the cohort’s low representation. Thirdly, although the performance of this nomogram was shown to be beneficial in our cohort, external validation is still necessary to be sure.

This study, which was the first to investigate the prognostic characteristics of patients with RPS for the first LR with the largest monocentric Asian experience, discovered that the postoperative DFI was associated with recurrence of the disease after LR; the initial surgical chemotherapy and high-grade tumors were associated with OS. In addition, two nomogram prediction models concerning OS and RFS, which can reliably predict the prognosis of FLR-RPS patients, were developed by our team.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the ethics committee of the South Hospital of Zhongshan Hospital/Shanghai Public Health Clinical Center. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

Conceptualization: AZ and WL. Methodology: AZ and YF. Software: AZ and YF. Validation: JW and JX. Formal analysis: AZ and JX. Investigation: AZ. Resources: YZ. Data curation: JW. Writing—original draft preparation: AZ. Writing—review and editing: LM. Visualization: YF. Supervision: HT. Project administration: AZ. Funding acquisition: YZ. All authors have read and agreed to the published version of the manuscript.

**REFERENCES**

1. Hui JY. Epidemiology and Etiology of Sarcomas. Surg Clin North Am (2016) 96(3):901–14. doi: 10.1016/j.scuc.2016.05.005
2. Bonvalot S, Rivoire M, Castaing M, Stocek E, Le Cesne A, Blay JY, et al. Primary Retroperitoneal Sarcomas: A Multivariable Analysis of Surgical Factors Associated With Local Control. J Clin Oncol (2009) 27(1):31–7. doi: 10.1200/JCO.2008.18.0802
3. Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach From the Trans-Atlantic RPS Working Group. Ann Surg Oncol (2016) 23(11):5331–40. doi: 10.1245/s10434-016-5336-7
4. Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic Subtype and Margin of Resection Predict Pattern of Recurrence and Survival for Retroperitoneal Liposarcoma. Ann Surg (2003) 238(3):358–70; discussion 370–1. doi: 10.1097/01.sla.0000086542.11899.38
5. Canter RJ, Qin LX, Ferrone CR, Maki RG, Singer S, Brennan MF. Why do Patients With Low-Grade Soft Tissue Sarcoma Die? Ann Surg Oncol (2008) 15(12):3550–60. doi: 10.1245/s10434-008-0163-0
6. Stojadinovic A, Yeh A, Brennan MF. Completely Resected Recurrent Soft Tissue Sarcoma: Primary Anatomic Site Governs Outcomes. J Am Coll Surg (2002) 194(4):436–47. doi: 10.1016/s1072-7515(02)01120-1
7. Linehan DC, Lewis JJ, Leung D, Brennan MF. Influence of Biologic Factors and Anatomic Site in Completely Resected Liposarcoma. J Clin Oncol (2000) 18(8):1637–43. doi: 10.1200/JCO.2000.18.8.1637
8. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal Soft-Tissue Sarcoma: Analysis of 500 Patients Treated and Followed at a Single Institution. Ann Surg (1998) 228(3):355–65. doi: 10.1097/00000658-19980900-00008
9. Park JO, Qin LX, Prete FP, Antonescu C, Brennan MF, Singer S. Predicting Outcome by Growth Rate of Locally Recurrent Retroperitoneal Liposarcoma: The One Centimeter Per Month Rule. Ann Surg (2009) 250(6):977–82. doi: 10.1097/sla.0b013e3181b2468b
10. Yang JY, Kong SH, Ahn HS, Lee HJ, Jeong SY, Ha J, et al. Prognostic Factors for Reoperation of Recurrent Retroperitoneal Sarcoma: The Role of Clinicopathological Factors Other Than Histologic Grade. J Surg Oncol (2015) 111(2):165–72. doi: 10.1002/jso.23783
11. Gronchi A, Miceli R, Allard MA, Callegaro D, Le Péchoux C, Fiore M, et al. Personalizing the Approach to Retroperitoneal Soft Tissue Sarcoma: Histology-Specific Patterns of Failure and Postrelapse Outcome After Primary Extended Resection. Ann Surg Oncol (2015) 22(5):1447–54. doi: 10.1245/s10434-014-4130-7
12. Lim HJ, Wong R, Koh YS, Ho ZS, Ong CJ, Farid M, et al. Characteristics and Outcomes of Locally Recurrent Retroperitoneal Sarcoma After First Relapse in a Single Tertiary Asian Centre and Applicability of the Sarculator. Front Oncol (2021) 11. doi: 10.3389/fonc.2021.730292
13. Raut CP, Callegaro D, Miceli R, Barretta F, Rutkowski P, Blay JY, et al. Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram From TARPSWG. Clin Cancer Res (2019) 25(8):2664–71. doi: 10.1158/1078-0432.CCR-18-2700
14. Troiani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, et al. Soft-Tissue Sarcomas of Adults: Study of Pathological Prognostic Variables and Definition of a Histopathological Grading System. Int J Cancer (1984) 33(1):37–42. doi: 10.1002/ijc.2910330108
15. Tattersall HL, Callegaro D, Ford SJ, Gronchi A. Staging, Nomograms and Other Predictive Tools in Retroperitoneal Soft Tissue Sarcoma. Chin Clin Oncol (2018) 7(4):36. doi: 10.21037/ccr.2018.08.01

Frontiers in Oncology | www.frontiersin.org April 2022 | Volume 12 | Article 856754
16. Camp RL, Dolled-Filhart M, Rimm DL. X-Tile: A New Bio-Informatics Tool for Biomarker Assessment and Outcome-Based Cut-Point Optimization. Clin Cancer Res (2004) 10(21):7252–9. doi: 10.1158/1078-0432.CCR-04-0713
17. Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons Learned From the Study of 10,000 Patients With Soft Tissue Sarcoma. Ann Surg (2014) 260(3):416–21; discussion 421-2. doi: 10.1097/SLA.0000000000000869
18. Ardoino I, Miceli R, Berselli M, Mariani L, Biganzoli E, Fiore M, et al. Histology-Specific Nomogram for Primary Retroperitoneal Soft Tissue Sarcoma. Cancer Am Cancer Soc (2010) 116(10):2429–36. doi: 10.1002/cncr.25057
19. Gronchi A, Miceli R, Shurell E, Eilber FC, Eilber FR, Anaya DA, et al. Outcome Prediction in Primary Resected Retroperitoneal Soft Tissue Sarcoma: Histology-Specific Overall Survival and Disease-Free Survival Nomograms Built on Major Sarcoma Center Data Sets. J Clin Oncol (2013) 31(13):1649–55. doi: 10.1200/JCO.2012.44.3747
20. Ikoma N, Torres KE, Lin HY, Ravi V, Roland CL, Mann GN, et al. Recurrence Patterns of Retroperitoneal Leiomyosarcoma and Impact of Salvage Surgery. J Surg Oncol (2017) 116(3):313–9. doi: 10.1002/jso.24667
21. Gyorki DE, Brennan MF. Management of Recurrent Retroperitoneal Sarcoma. J Surg Oncol (2014) 109(1):53–9. doi: 10.1002/jso.23463
22. Grobmyer SR, Wilson JP, Apel B, Knapik J, Bell WC, Kim T, et al. Recurrent Retroperitoneal Sarcoma: Impact of Biology and Therapy on Outcomes. J Am Coll Surg (2010) 210(5):602–8, 608-10. doi: 10.1016/j.jamcollsurg.2009.12.024
23. Gronchi A, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, et al. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-Institutional Collaborative RPS Working Group. Ann Surg (2016) 263(5):1002–9. doi: 10.1097/SLA.0000000000001447
24. Nessim C, Raut CP, Callegaro D, Barrepta F, Miceli R, Fairweather M, et al. Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). Ann Surg Oncol (2021) 28(12):7854–63. doi: 10.1245/s10434-021-10024-y
25. Stojadinovic A, Leung DH, Allen P, Lewis JJ, Jaques DP, Brennan MF. Primary Adult Soft Tissue Sarcoma: Time-Dependent Influence of Prognostic Variables. J Clin Oncol (2002) 20(21):4344–52. doi: 10.1200/JCO.2002.07.154
26. Pervaiz N, Collerjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A Systematic Meta-Analysis of Randomized Controlled Trials of Adjuvant Chemotherapy for Localized Resectable Soft-Tissue Sarcoma. Cancer Am Cancer Soc (2008) 113(3):573–81. doi: 10.1002/cncr.23592
27. Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, et al. Adjuvant Chemotherapy With Doxorubicin, Ifosfamide, and Lenograstim for Resected Soft-Tissue Sarcoma (EORTC 62931): A Multicentre Randomised Controlled Trial. Lancet Oncol (2012) 13(10):1045–54. doi: 10.1016/S1470-2045(12)70346-7
28. Miura JT, Charlson J, Gamblin TC, Eastwood D, Banerjee A, Johnston FM, et al. Impact of Chemotherapy on Survival in Surgically Resected Retroperitoneal Sarcoma. Eur J Surg Oncol (2015) 41(10):1386–92. doi: 10.1016/j.ejso.2015.07.014

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhuang, Lu, Fang, Ma, Xu, Wang, Tong and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.